Discovery of Novel SARS-CoV-2 3CLpro Inhibitors from Natural Products using FRET-based Assay
ETFGg was identified as a promising 3CLpro inhibitor with high binding stability, highlighting its potential as a lead compound for the development of anti-- COVID-19 drugs.
Authors
- JiXia WANG
- Liangji Liu
- Xi Liang (ORCID: https://orcid.org/0000-0002-0674-2246)
- Longying Liu
- Huijie Li (ORCID: https://orcid.org/0000-0002-3926-0323)
- Tianyu Zhang (ORCID: https://orcid.org/0009-0004-8510-3486)
- H. Zhou (ORCID: https://orcid.org/0000-0003-2060-0436)
- Pan Wang
- Xianlong Ye
- Fangfang Xu
- Hongming Tang
- Tao Hou
Institutions
- Dalian Institute of Chemical Physics (CN)
- Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Current Medicinal Chemistry
- Published
- 2026-02-09
- DOI
- https://doi.org/10.2174/0109298673405748251114095746
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00